Jensen Investment Management Inc. Has $326.07 Million Holdings in Johnson & Johnson (JNJ)

Jensen Investment Management Inc. lowered its stake in Johnson & Johnson (NYSE:JNJ) by 8.1% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 2,464,813 shares of the company’s stock after selling 217,445 shares during the period. Johnson & Johnson makes up about 4.5% of Jensen Investment Management Inc.’s investment portfolio, making the stock its 9th largest holding. Jensen Investment Management Inc. owned approximately 0.09% of Johnson & Johnson worth $326,070,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Mitsubishi UFJ Securities Holdings Co. Ltd. increased its holdings in shares of Johnson & Johnson by 29.9% in the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock valued at $115,000 after buying an additional 200 shares in the last quarter. Lenox Wealth Advisors Inc. increased its holdings in shares of Johnson & Johnson by 0.6% in the second quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock valued at $116,000 after buying an additional 5 shares in the last quarter. Shine Investment Advisory Services Inc. bought a new position in shares of Johnson & Johnson in the second quarter valued at $177,000. Ullmann Financial Group Inc. bought a new position in shares of Johnson & Johnson in the first quarter valued at $186,000. Finally, Puplava Financial Services Inc. bought a new position in shares of Johnson & Johnson in the second quarter valued at $202,000. 65.90% of the stock is currently owned by institutional investors.

Johnson & Johnson (JNJ) traded up $1.40 during midday trading on Wednesday, hitting $141.07. 1,120,404 shares of the stock were exchanged, compared to its average volume of 5,877,685. Johnson & Johnson has a 1-year low of $109.32 and a 1-year high of $144.35. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.32 and a quick ratio of 1.02. The firm has a market capitalization of $373,453.13, a P/E ratio of 19.47, a PEG ratio of 2.83 and a beta of 0.80.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, October 17th. The company reported $1.90 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.80 by $0.10. Johnson & Johnson had a net margin of 21.28% and a return on equity of 27.38%. The business had revenue of $19.65 billion for the quarter, compared to the consensus estimate of $19.29 billion. During the same period in the prior year, the business posted $1.68 earnings per share. Johnson & Johnson’s revenue for the quarter was up 10.3% compared to the same quarter last year. analysts anticipate that Johnson & Johnson will post 7.28 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 12th. Stockholders of record on Tuesday, November 28th will be paid a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.38%. The ex-dividend date of this dividend is Monday, November 27th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 58.33%.

Several brokerages have issued reports on JNJ. J P Morgan Chase & Co boosted their target price on shares of Johnson & Johnson from $140.00 to $148.00 and gave the company an “overweight” rating in a research note on Wednesday, August 16th. Citigroup began coverage on shares of Johnson & Johnson in a research note on Monday, September 25th. They set a “neutral” rating and a $140.00 target price on the stock. Jefferies Group set a $145.00 target price on shares of Johnson & Johnson and gave the company a “hold” rating in a research note on Tuesday, August 15th. BMO Capital Markets reissued a “positive” rating and set a $152.00 target price (up from $145.00) on shares of Johnson & Johnson in a research note on Wednesday, October 18th. Finally, Royal Bank Of Canada boosted their target price on shares of Johnson & Johnson from $144.00 to $147.00 and gave the company an “outperform” rating in a research note on Wednesday, October 18th. Four investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and eleven have assigned a buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $144.59.

ILLEGAL ACTIVITY NOTICE: This piece was originally published by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this piece on another site, it was stolen and reposted in violation of United States and international trademark & copyright legislation. The correct version of this piece can be accessed at https://stocknewstimes.com/2017/12/06/jensen-investment-management-inc-has-326-07-million-holdings-in-johnson-johnson-jnj.html.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply